Abstract
AbstractAnti-nuclear antibodies (ANA) are on the front line of diagnosing connective tissue disease. Beyond their diagnostic and prognostic utility, these biomarkers could also have a direct pathogenetic role. Thus, in systemic sclerosis the three most frequent specificities which are anti-topoisomerase-I aAb (anti-TOPO-I or Scl70), anti-centromeres and anti-RNA polymerase-III are integrated into the classification of the disease. New antigenic specificities are also associated with the diagnosis of systemic sclerosis. The time frame for theses autoantibodies appearance, their correlation with phenotypes and/or prognoses as well as the therapeutic efficacy of certain biotherapies argue in favor of a pathogenetic role of these aAb beyond their role as diagnostic marker. The involvement of ANA in the pathophysiology of SSc opens the way to new fields of research in this area.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
